We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+82.63%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.06B
AUM Growth
+$2.1B
Cap. Flow
+$394M
Cap. Flow %
7.79%
Top 10 Hldgs %
66.41%
Holding
52
New
9
Increased
18
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$88.8M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$62.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$61M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$52.3M
5
IMMU
Immunomedics Inc
IMMU
+$51.2M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$43M
2
SAGE
Sage Therapeutics
SAGE
+$28.7M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$15.2M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
26
DELISTED
Trillium Therapeutics Inc.
TRIL
$38.4M 0.76%
4,750,000
-200,000
-4% -$1.24M
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
$36.9M 0.73%
4,565,655
+200,000
+5% +$1.76M
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$36.2M 0.72%
+7,100,000
New +$29.6M
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.24B
$35.1M 0.69%
2,800,000
+28,000
+1% +$356K
MRNS
30
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$30.4M 0.6%
2,990,000
+1,440,000
+93% +$13.2M
AUPH icon
31
Aurinia Pharmaceuticals
AUPH
$2.04B
$27.1M 0.54%
1,670,000
-55,000
-3% -$881K
BDTX icon
32
Black Diamond Therapeutics
BDTX
$108M
$22.1M 0.44%
525,000
+3,250
+0.6% +$120K
TVTX icon
33
Travere Therapeutics
TVTX
$6B
$21.4M 0.42%
+1,050,000
New +$16.7M
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
$18.3M 0.36%
5,250,000
-250,000
-5% -$721K
KURA icon
35
Kura Oncology
KURA
$839M
$17.1M 0.34%
+1,050,000
New +$15.1M
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$16.5M 0.33%
+585,000
New +$16.9M
TCDA
37
DELISTED
Tricida, Inc. Common Stock
TCDA
$16.5M 0.33%
600,000
-765,000
-56% -$20.8M
PTCT icon
38
PTC Therapeutics
PTCT
$5.87B
$16.5M 0.33%
324,750
-875,250
-73% -$43M
FENC icon
39
Fennec Pharmaceuticals
FENC
$365M
$13.9M 0.28%
1,670,000
+564,001
+51% +$4.19M
AMRN
40
Amarin Corp
AMRN
$301M
$13.8M 0.27%
100,000
– –
RVMD icon
41
Revolution Medicines
RVMD
$42.3B
$9.6M 0.19%
304,000
-146,000
-32% -$4.59M
BDSI
42
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$8.87M 0.18%
2,034,900
-965,100
-32% -$4.34M
CRDF icon
43
Cardiff Oncology
CRDF
$74.1M
$5.01M 0.1%
+1,000,000
New +$2.05M
ALIM
44
DELISTED
Alimera Sciences
ALIM
$2.62M 0.05%
415,999
– –
ADAP
45
CALL
DELISTED
Adaptimmune Therapeutics
ADAP
$70K ﹤0.01%
+200,000
New +$1.26M
ACAD icon
46
Acadia Pharmaceuticals
ACAD
$4.97B
– –
-145,000
Closed -$6.13M
AGEN
47
Agenus
AGEN
$324M
– –
-140,113
Closed -$6.74M
AMRN
48
CALL
Amarin Corp
AMRN
$301M
– –
-50,000
Closed -$10K
IOVA icon
49
CALL
Iovance Biotherapeutics
IOVA
$2.69B
– –
-1,250,000
Closed -$3.13M
SAGE
50
DELISTED
Sage Therapeutics
SAGE
– –
-1,000,000
Closed -$28.7M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Avoro Capital Advisors held 52 positions worth $5.06B, up 71% from $2.96B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $394M of net new capital in Q2 2020, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was Mersana Therapeutics: 260,000 shares worth $152M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $43M trimmed.

  • Avoro Capital Advisors's largest Q2 2020 buy was Mersana Therapeutics: 260,000 shares worth $152M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020, an estimated $61M increase.
  • Avoro Capital Advisors's biggest Q2 2020 reduction was PTC Therapeutics, cutting an estimated $43M.
  • Avoro Capital Advisors fully exited Sage Therapeutics in Q2 2020, selling an estimated $28.7M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $5.06B portfolio in Q2 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 7 in Q2 2020.
  • Avoro Capital Advisors's portfolio value rose 71% quarter-over-quarter to $5.06B.

Based on Avoro Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.